Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
01:50am, Wednesday, 07'th May 2025
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Obesity drugmaker Novo Nordisk cuts 2025 outlook, posts Q1 profit above forecast
01:35am, Wednesday, 07'th May 2025
Obesity drugmaker Novo Nordisk on Wednesday posted first-quarter operating profit above analyst forecasts and cut its operating profit and sales outlook for the year.
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
06:48pm, Tuesday, 06'th May 2025
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share.
04:30pm, Tuesday, 06'th May 2025
Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has brought stumbles for Novo over the past year.
Hims & Hers (NYSE: HIMS) Earnings Are In (Live Coverage)
12:05pm, Tuesday, 06'th May 2025
Live Updates Live Coverage Has Ended HIMS forward guidance is exciting 5:02 pm by Joel South HOLY MOLY $HIMS JUST GUIDED TO $6.5B IN 2030 SALES WITH 20% EBITDA MARGINS pic.twitter.com/9w2fDU8rlQ — S
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
10:55am, Tuesday, 06'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novo Resources Releases Updated Corporate Presentation
08:00am, Tuesday, 06'th May 2025
PERTH, West Australia, May 06, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate pres
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
08:00am, Tuesday, 06'th May 2025
Bagsværd, Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company's industry-leading portfolio across metabolic and cardiovascular health will be presented at the upco
HIMS Earnings Ahead: Wegovy Offers Upside, Analysts Advise Caution
11:30am, Monday, 05'th May 2025
"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
10:15am, Monday, 05'th May 2025
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
3 No-Brainer Stocks to Buy in May
06:45am, Monday, 05'th May 2025
Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the sum
Eli Lilly: Don't Overthink This Buying Opportunity
09:00am, Saturday, 03'rd May 2025
Eli Lilly faced a 12% drop due to CVS formulary changes favoring Novo Nordisk, but I explain why this seems overstated. Lilly has gained control as the US market leader for GLP-1 drugs, and is still m
Novo Nordisk: FDA Accepts New Drug Application for Oral Wegovy
03:01pm, Friday, 02'nd May 2025
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management.
U.S. FDA accepts Novo Nordisk's application for oral Wegovy
02:41pm, Friday, 02'nd May 2025
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker sa
